TransMedics Group, a provider of end-to-end technology & expert clinical service solutions, completed the acquisition of Bridge to Life, a global supplier of organ preservation and perfusion technologies. Financial terms were not disclosed. “This transaction enables us to strengthen our financial position and adequately fund the continued expansion of our leading share in the global preservation solutions market as well as continue the development of our VitaSmart abdominal organ perfusion device. In May 2023, we announced the completion of enrollment of our pivotal HOPE trial, and we expect to submit our Premarket Approval application to the Food and Drug Administration later this year," Don Webber, Bridge to Life CEO.